Klertis

Sunitinib, the active ingredient in Klertis, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is indicated for the treatment of renal cell carcinoma, gastrointestinal stromal tumor and pancreatic neuroendocrine tumor in adult patients.

GNH USA supplies Klertis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Sunitinib is a targeted oral therapy used in several solid‑tumor indications.

Renal cell carcinoma: slows disease progression and may improve overall survival in adults with advanced disease. Gastrointestinal stromal tumor (GIST): inhibits tumor growth after failure of first‑line therapy. Pancreatic neuroendocrine tumor: reduces tumor burden and extends progression‑free survival in metastatic cases.

Sunitinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require fluid replacement. - Nausea: feeling of sickness often managed with anti‑emetics. - Hand‑foot syndrome: redness, swelling, or pain on palms and soles. - Hypertension: elevated blood pressure requiring monitoring. - Decreased appetite: reduced desire to eat.

Serious or Rare Side Effects: - Cardiac dysfunction: signs of heart failure or reduced ejection fraction. - Hemorrhage: unexpected bleeding, including gastrointestinal. - Thromboembolic events: blood clots in veins or arteries. - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe neutropenia: markedly low white blood cell count increasing infection risk.

Before initiating therapy, clinicians should assess patient suitability and monitor for potential complications. - Baseline cardiac evaluation: perform ECG or echocardiogram to detect pre‑existing dysfunction. - Blood pressure monitoring: check regularly and treat hypertension promptly. - Liver function tests: assess enzymes before and during treatment. - Hematologic surveillance: monitor complete blood count for neutropenia or anemia. - Pregnancy and lactation: avoid use; discuss contraception and breastfeeding risks. - Store at below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Sunitinib can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sunitinib exposure and toxicity. - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic levels. - Anticoagulants (e.g., warfarin): heightened risk of bleeding.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive blood pressure effects may require dose adjustment. - CYP2C9 substrates (e.g., warfarin at lower doses): monitor INR closely. - Gastric pH modifiers (e.g., proton pump inhibitors): may affect absorption, observe clinical response.